Peijia Medical Ltd. (HK:9996)
:9996
Want to see HK:9996 full AI Analyst Report?
9996 Stock Chart & Stats
HK$6.51
-HK$0.07(-1.80%)
At close: 4:00 PM EST
HK$6.51
-HK$0.07(-1.80%)
Day’s Range― - ―
52-Week RangeHK$5.00 - HK$9.36
Previous CloseN/A
Volume6.00K
Average Volume (3M)1.88M
Market Cap
HK$4.43B
Enterprise ValueHK$3.57B
Total Cash (Recent Filing)HK$610.52M
Total Debt (Recent Filing)HK$434.22M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding672,060,670
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio1.54
Price to Book (P/B)1.95
Price to Sales (P/S)5.17
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.33Price Target Upside58.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$943.63M
Bulls Say, Bears Say
Bulls Say
High Gross Margin (~67%)Sustained ~67% gross margins give structural protection for profitability as volumes scale. High product-level margins support reinvestment in R&D, commercialization, and clinical evidence generation, enabling durable unit economics even with competitive pricing pressure.
Low Leverage (debt/equity ~0.24)Low financial leverage reduces refinancing and interest risks while the company matures. This capitalization provides flexibility to fund clinical programs and geographic expansion without immediate pressure to cut investment, important during the transition to consistent cash generation.
Focus On TAVR And Neurovascular DevicesConcentration on minimally invasive structural heart and neurovascular implants aligns with long-term secular shifts toward catheter-based therapies and ageing populations. High clinical barriers and procedure-driven adoption create durable market demand and differentiation versus commoditized device segments.
Bears Say
Persistent Operating LossesContinued negative EBIT and ~-29% net margin indicate the company has not yet converted revenue growth into profitability. Prolonged operating losses can deplete capital, limit strategic options, and force cost-cutting that could slow commercialization and clinical adoption momentum.
Material Negative Free Cash FlowLarge negative free cash flow (~-325M) signals ongoing cash burn and reliance on external financing. This constrains organic reinvestment, increases dilution or debt risk, and makes long-term scaling dependent on successful funding or rapid improvement in cash conversion.
Negative Returns On Equity (~-11%)A negative ROE shows the company is not generating returns on invested capital, reducing shareholder value over time. If sustained, negative returns make it harder to attract long-term capital and may force reprioritization away from growth initiatives toward near-term profitability.
Peijia Medical Ltd. News
9996 FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was HK$5.00 and its highest was HK$9.36 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is HK$4.43B.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 121 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.22 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.22.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Undervalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 672,060,670 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -HK$0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.792%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in HK:9996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.
9996 Stock 12 Month Forecast
Average Price Target
HK$10.33
▲(58.68% Upside)
Technical Analysis
MicroPort Scientific
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---